Call for Paper
Submission is open for Volume 10 Number 3 - 4 July - December 2022 Click here to submit paper
Indexing
Chairman NMA
Dr Umar Mohammed
Chairman NMA Sokoto
View Publication
| Publication Title : | PREVALENCE OF RIFAMPICIN-RESISTANT TUBERCULOSIS AND ITS ASSOCIATED FACTORS IN A TERTIARY HEALTH CARE CENTRE, SOUTH-WEST NIGERIA: A 5-YEAR REVIEW |
| Author(s) : | Ojewuyi AR, Odeyemi AO, Odeyemi AO, Olotu AA, Oladipo TS |
| Abstract : | Background: Tuberculosis is a chronic disease with associated high morbidity and mortality. In recent decades, there has been an increase in resistance to drugs used in the treatment of tuberculosis. This is a major stumbling block in the global fight against tuberculosis. This study was to demonstrate the current prevalence of rifampicinresistant tuberculosis and its associated predisposing factors in a Teaching Hospital in Nigeria. Methods: This was a cross-sectional retrospective study involving 359 consecutive patients with bacteriologically confirmed tuberculosis seen between January 2015 and December 2019. Drug susceptibility testing was performed for rifampicin using GeneXpert MTB/RIF assay. Relevant information was obtained from the clinical records of the patients with the use of a well-structured proforma. The data obtained were analysed using the Statistical Package for Social Sciences (SPSS) version 23.0. Results: There were a total of 359 patients out of which the majority, 235 (65.5%) were males. The mean age was 39.78+16.31 (range 1 - 90 years). A larger percentage of the subjects were new cases of tuberculosis (n=312, 86.9%), 49(13.6%) were HIV positive. The overall prevalence of rifampicin resistance found was 2.5% (n=9/359). There was a significant association between gender (p=0.005) and re-treatment (p=0.003). There was no significant association between rifampicin resistance and other factors including age and HIV. Conclusion: Male gender and patients on re-treatment for tuberculosis are more at risk of developing resistance to rifampicin in our environment. There is a need to ensure compliance with all guidelines in the management of tuberculosis to prevent an increase in drug resistance. |
| DOI : | 10.47837/CMJ.202191.2 |
| Download : | Download |
| Print : |